ETF Holdings Breakdown of KROS

KROS institutional holdings

The adjusted close for KROS on 2025-11-11 was 16.90

The following institutional investment holdings of KROS have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	25,687	USD 434,110 -0.8%	16.90
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	25,687	USD 434,110 -0.8%	16.90
Total =		51,374	USD 868,220

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with KROS

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $30.00

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year […] - 2025-09-22 02:24:53

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month […] - 2025-08-25 02:16:48

XTX Topco Ltd Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the first quarter, Holdings Channel reports. The institutional investor purchased 48,121 shares of the company’s stock, valued at approximately $490,000. A number of other institutional investors also recently modified their holdings of the business. Braidwell LP lifted […] - 2025-08-08 04:38:55

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $30.56

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among […] - 2025-07-09 02:33:04

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Bank of America

Keros Therapeutics (NASDAQ:KROS – Get Free Report) was downgraded by Bank of America from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, Marketbeat reports. They currently have a $18.00 price target on the stock, down from their prior price target of $32.00. Bank of America‘s […] - 2025-06-12 02:23:35

Noteworthy Monday Option Activity: KROS, RH, ADBE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Keros Therapeutics Inc (Symbol: KROS), where a total of 6,554 contracts have traded so far, representing approximately 655,400 underlying shares. That amounts to about 1 - 2025-06-09 16:18:51

46,110 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 46,110 shares of the company’s stock, valued at approximately $730,000. Several other large investors have also recently bought and sold shares of […] - 2025-05-23 04:26:53

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month […] - 2025-05-22 05:30:55

Keros Therapeutics, Inc. (NASDAQ:KROS) Position Increased by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 207.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,371 shares of the company’s stock after purchasing an additional 4,976 shares during the period. […] - 2025-05-01 05:40:59

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 67.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,321 shares of the company’s stock after selling 68,995 shares during the quarter. Russell Investments […] - 2025-04-24 04:44:48

Geode Capital Management LLC Buys 39,815 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Geode Capital Management LLC raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 5.5% during the fourth quarter, HoldingsChannel reports. The fund owned 765,436 shares of the company’s stock after acquiring an additional 39,815 shares during the quarter. Geode Capital Management LLC’s holdings in Keros Therapeutics were worth $12,120,000 at […] - 2025-04-22 05:13:07

KLP Kapitalforvaltning AS Invests $90,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

KLP Kapitalforvaltning AS purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,700 shares of the company’s stock, valued at approximately $90,000. A number of other hedge funds […] - 2025-04-11 05:40:58

Wedbush Reiterates “Neutral” Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at Wedbush in a research note issued on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 49.40% from the stock’s previous close. Several other equities analysts […] - 2025-04-03 04:34:50

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average […] - 2025-04-02 05:03:11

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $52.56

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price […] - 2025-02-11 06:30:53

Back to Listing

Disclaimer